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ABSTRACT 26 
Reducing Campylobacter spp. carriage in poultry is challenging, but essential to 27 
control this major cause of human bacterial gastroenteritis worldwide. Although much 28 
is known about the mechanisms and route of Campylobacter spp. colonization in 29 
poultry the literature is scarce on antibiotic-free solutions to combat Campylobacter 30 
spp. colonization in poultry. In vitro and in vivo studies were conducted to investigate 31 
the role of TYPLEX
® 
Chelate (ferric tyrosine), a novel feed additive, in inhibiting 32 
Campylobacter jejuni (C. jejuni) biofilm formation and reducing C. jejuni and 33 
Escherichia coli (E. coli) colonization in broiler chickens at market age. In an in vitro 34 
study, the inhibitory effect on C. jejuni biofilm formation using a plastic bead assay 35 
was investigated. The results demonstrated that TYPLEX
® 
Chelate significantly 36 
reduces biofilm formation. In an in vivo study, 800 broilers (one-day old) were 37 
randomly allocated to 4 dietary treatments in a randomised block design, each having 38 
10 replicate pens with 20 birds per pen. At day 21, all birds were challenged with C. 39 
jejuni via seeded litter. At day 42, caecal samples were collected and tested for 40 
volatile fatty acid (VFA) concentrations, C. jejuni and E. coli counts. The results 41 
showed that TYPLEX
® 
Chelate reduced the carriage of C. jejuni and E. coli in poultry 42 
by 2 and 1 log10 per gram caecal sample, respectively, and increased caecal VFA 43 
concentrations. These findings support TYPLEX
® 
Chelate as a novel non-antibiotic 44 
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feed additive that may help produce poultry with a lower public health risk of 45 
Campylobacteriosis. 46 
KEY WORDS 47 
Campylobacter, biofilm, volatile fatty acid, feed additive, food safety 48 
INTRODUCTION 49 
Campylobacter spp. infections are a major cause of human bacterial gastroenteritis 50 
and pose a serious health burden worldwide, accounting for 400-500 million cases of 51 
diarrhoea each year (Ruiz-Palacios, 2007). A significant proportion of health care 52 
costs are associated with sequelae linked to Campylobacteriosis such as Guillain-53 
Barré syndrome, reactive arthritis and irritable bowel syndrome (WHO, 2013). 54 
Despite several government programs and awareness campaigns to reduce 55 
Campylobacter spp. little reduction is reported in the numbers of bacterium in animals 56 
and/or animal products in retail outlets (Robyn et al., 2015). It is estimated that 57 
foodborne transmission contributes to 58% of the global disease burden (Hald et al., 58 
2015). 59 
Chicken, pork and beef are reported as significant foodborne sources of 60 
Campylobacter with presence of the pathogen at high concentrations found 61 
throughout the food chain (Miller and Mandrell, 2005). The strong adhesion 62 
capability of Campylobacter strains could partly explain the rapid cross-63 
contamination or re-contamination of food products, and may be the most significant 64 
mode of survival for Campylobacter in the food chain (Sulaeman et al., 2010).  65 
Campylobacter infection is dependent on motility mediated by polar flagella A 66 
(FlaA) and adhesion and  biofilm promoting ability of the Major Outer Membrane 67 
Protein (MOMP) (Ashgar et al., 2007; Muller et al., 2007 and Min et al., 2009; 68 
Mahdavi et al., 2014). Considering such idiosyncrasy, it is easy for Campylobacter to 69 
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colonize live animals and survive transitionally in the food chain or in biofilms before 70 
reaching the intestinal tract of humans (Buswell et al., 1998; Trachoo and Frank, 71 
2002; Miller and Mandrell, 2005; Lehtola et al., 2006; Sanders et al., 2008).  72 
Biofilms are accumulations of microorganisms embedded in an extracellular matrix 73 
(ECM) which adheres to solid biological or non-biotic surfaces (Costerton, 1995; 74 
Kalmokoff et al., 2006). The ECM comprises proteins, polysaccharides, nucleic acids 75 
and phospholipids (Stoodley et al., 2004). Foodborne bacterial pathogens can either 76 
form biofilms on inert surfaces or can reach and integrate into pre-established 77 
biofilms.  78 
Increase in caecal volatile fatty acid (VFA) concentrations, indicating fermentation by 79 
anaerobic bacteria, are found to be negatively correlated with the number of 80 
Enterobacteriaceae in broiler chickens (Van Der et al., 2000; Kubena et al., 2001). 81 
Several strategies such as reduction of environmental exposure to Campylobacter by 82 
hygiene and biosecurity measures, water treatment, use of plant-derived feed 83 
additives, use of bacteriophage, bacteriocin therapies, vaccination, passive 84 
immunization, use of pre- and probiotics and genetic selection have been investigated 85 
to control on-farm Campylobacter contamination (Sahin et al., 2003; Chaveerach et 86 
al., 2004; Carrillo et al., 2005; Calderon-Gomez et al., 2009; Lin, 2009; Buckley et 87 
al., 2010; Svetoch and Stern, 2010; Hermans et al., 2010; Hermans et al., 2011). 88 
Despite all these efforts Campylobacter remains a major cause of human 89 
gastroenteritis and a priority for the development of new control strategies. In 90 
addition, use of antibiotics in both animal and human medicine can influence the 91 
development of antibiotic–resistant Campylobacter and is increasingly becoming a 92 
challenge for food safety and public health (Luangtongkum et al., 2009). The authors 93 
postulated that the novel feed additive, TYPLEX
®
 Chelate, a synthetic complex of L-94 
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tyrosine and Fe (III), exerts a unique action on enteropathogens by preventing the 95 
formation of biofilms at chyme/mucosal and other interfaces. Based on the non-96 
antimicrobial nature of ferric tyrosine the current studies were designed to 97 
demonstrate that TYPLEX
®
 Chelate inhibits C. jejuni biofilm formation (in vitro), 98 
increases caecal VFA concentrations (in vivo) and thus has an ability to reduce caecal 99 
colonization of C. jejuni and E. coli in broilers at slaughter. 100 
MATERIALS AND METHODS 101 
Feed additive 102 
TYPLEX
®
 Chelate (Akeso Biomedical, Inc., Waltham, MA), a complex containing 103 
tyrosine and iron (ferric tyrosine), was the novel feed additive used in these studies.  104 
Experimental diets 105 
Basal iso-nitrogenous and iso-energetic wheat-soyabean meal control diets (T1) were 106 
manufactured as one batch for each feeding phase i.e. starter (day 0-21) and grower 107 
(day 21-42). Three additional treatments (T2 to T4) were generated by addition of 108 
TYPLEX
® 
Chelate to T1 at 0.02, 0.05 and 0.20 g/kg feed, respectively. Diets were 109 
manufactured with coccidiostats but contained no veterinary antibiotics. The 110 
ingredients, premixes and the calculated analyses of the starter and grower diets are 111 
presented in Table 1. Diets were analysed for dry matter, nitrogen, ether extract and 112 
iron. Total nitrogen content of diet was determined by the combustion method 113 
(AOAC Method 968.06) whereas ether extract was determined in a soxhlet extractor 114 
(AOAC Method 922.06). Iron content was determined using Inductively Coupled 115 
Plasma – Optical Emission Spectroscopy (AOAC Method 990.08) following 116 
digestion, in turn, in concentrated Nitric and Hydrochoric acid. Coloured tracers 117 
(Micro-Tracers Inc, San Francisco) were added to TYPLEX
TM
 chelate at 10% w/w, to 118 
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enable visual confirmation of TYPLEX
TM
 chelate content and uniform mixing in feed 119 
samples.  120 
 121 
In vitro assessment of C. jejuni biofilm inhibition in a simulated gut environment 122 
using a plastic bead assay 123 
A plastic bead assay (O'Toole and Kolter, 1998; Stepanovic et al., 2000) with some 124 
modifications for suitability with C. jejuni was carried out in vitro to show that the 125 
TYPLEX
®
 Chelate extracted from the experimental diets has an inhibitory effect on 126 
C. jejuni biofilm formation. 127 
Extraction of TYPLEX
®
 chelate from the experimental diets. 10 g aliquots of 128 
feed from all experimental diets (T1 to T4) for each phase were homogenised to very 129 
fine particles (around 100 µm) and mixed with 50 ml (1:5) of buffer (20 mM 130 
KCl/HCl; pH 3.4). The feed/buffer mixtures were autoclaved (high-pressure saturated 131 
steam at 121°C for around 15–20 minutes, 3 cycles). The high heat and pressure of 132 
the autoclave resulted in extraction of the TYPLEX
®
 Chelate from the feeds while 133 
retaining its physical properties. The resulting suspensions were then filtered using 134 
filter paper (25 µm filter). The pH of all filtered samples was measured and found to 135 
be between 6.2 to 6.5. 136 
Bead Assay. C. jejuni strain NCTC11168 was grown overnight in 3 ml of sterile brain 137 
heart infusion (BHI) broth under microaerophilic conditions (85% nitrogen, 10% 138 
carbon dioxide and 5% oxygen) at 42°C on modified Campylobacter-selective 139 
charcoal cefoperazone desoxycholate (CCDA). The optical density at a wavelength of 140 
600 nm (OD600) of these cultures were measured, then they were used to inoculate a 141 
feed extract + BHI suspension (1:4 dilution) to achieve a final OD600 of 0.02.  142 
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Two sterile plastic beads per dietary treatment were placed into 2.5 ml of BHI, with 143 
0.5 ml of the extracted feeds
 
and inoculated with C. jejuni. The beads were then 144 
incubated at 42°C for 48 hr. Following incubation, the beads were gently washed 145 
twice (5x dipping each) in phosphate buffered saline (PBS), placed into 1 ml of PBS 146 
and vigorously vortexed for 30 s prior to centrifuging at 3000 rpm. The PBS 147 
containing bacterial cells released from the biofilm was serially diluted and 3 x 5 µl 148 
aliquots of each dilution were spotted onto CCDA agar plates for quantification 149 
(Thermo-Fisher plates, 3 plates/bead, two beads/treatment, 6 samples/treatment). The 150 
plates were subsequently incubated microaerophilically at 42°C for 48 hrs and 151 
colonies were counted and expressed as cfu/ml. The same experiment was carried out 152 
in triplicate. 153 
Seeder litter challenge to colonise chicken with C. jejuni in vivo  154 
To confirm in vitro findings, an in vivo study was designed to investigate the efficacy 155 
of TYPLEX
®
 Chelate under farm conditions. A total of 800 male broiler chickens 156 
(Ross 308) were allocated randomly to pens in 4 dietary treatments (T1 to T4), with 157 
pens distributed using a randomized complete block design. Each treatment had 10 158 
replicate floor pens with 20 chicks per pen. Birds were reared on fresh wood shavings 159 
in clean pens having European Union maximum stocking density at 42 d of 38 kg/m
2
. 160 
At 21 days of age all birds were challenged with C. jejuni seeded litter. Diets were fed 161 
ad libitum for 42 days in mash form; body weight and feed intake of each replicate 162 
pen were recorded to calculate the global zootechnical data (days 0-39). At the end of 163 
the study (day 42), all birds were humanely killed through cervical dislocation and 164 
caecal samples were collected from 10 birds/pen and used for C. jejuni and E. coli 165 
enumeration, and 2 birds/pen for caecal VFA analysis. 166 
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The in vivo study (AU AE 37-2016) was carried out under the Animals Scientific 167 
Procedures Act (1986) and approved by the ethical review committee of Scotland’s 168 
Rural College (SRUC). 169 
Seeded litter challenge procedure. Approximately 20 kg of used poultry litter 170 
was taken from a recently completed broiler study. The litter (not tested for any 171 
pathogen) was placed in an oven at 80°C until a constant weight was obtained, then 172 
divided into 400 g batches in forty trays (each tray was approximately 38 × 28 × 8 173 
cm). Each dried reused litter tray was reconstituted with 1000 ml of deionised water. 174 
Trays were then seeded with a mixture of Mueller-Hinton (MH) broth, 175 
Campylobacter suspension (4.5 x 10
5
 cfu C. jejuni/ml) and dried hen droppings (20 176 
ml: 10 ml: 10g). The hen droppings were dried in the same way as the litter. 177 
Campylobacter isolates were obtained from caecal samples taken from three different 178 
commercial poultry farms and stored at -80°C in bead cryopreservation vials 179 
(Technical Service Consultants, UK). C. jejuni (individual strains were not identified) 180 
were resuscitated on Blood Agar No. 2 with Horse Blood (BA) plates (Oxoid, UK). 181 
These cultures were used to prepare lawn plates on further BA plates, incubated for 182 
40 – 48 hrs at 41.5°C, in boxes with a microaerophilic atmosphere generation system 183 
(CampyGen, Oxoid, UK). The lawn plates were harvested by adding 5 ml MH broth, 184 
gently detaching the culture with a sterile spreader and decanting to a container. The 185 
suspension was then adjusted with further MH broth to OD600 of 0.19 – 0.21 186 
(approximately 1.5 × 10
5
 cfu.ml
-1
). The bacterial suspension, broth and droppings 187 
were mixed and spread evenly on the top of the litter tray. The tray was then placed in 188 
a pen near the feeder. 189 
Isolation and enumeration of C. jejuni from caeca. A sterile scalpel was used 190 
to cut off the blind end of both caecal sacks from each chicken. For each sample, 0.5g 191 
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of content from each caecal sac (in total 1g) was weighed out into sterile Universal 192 
bottles. At each sampling, a total of 2g caecal content was diluted with 4 ml of sterile 193 
Maximum Recovery Diluent (MRD), which was added to each Universal container 194 
and mixed thoroughly. This constituted the 1:2 dilutions (w/v). A further 8 serial 195 
dilutions were made in MRD. Then, 5-10 µL of each dilution was spotted on CCDA, 196 
MRS, Brilliance or chromogenic plates (Oxoid PO0119) and left to dry. Plates were 197 
incubated microaerophilically at 41.5°C ± 2.0°C for 24-48 hrs. Following incubation, 198 
plates were assessed for the presence or absence of thermotolerant Campylobacter 199 
species. In addition, plates of an appropriate dilution level were selected and colonies 200 
enumerated. As a confirmatory measurement, two colonies from each presumptively 201 
positive plate were selected and sub-cultured onto paired blood agar plates (Oxoid 202 
PB0114). These plates were incubated at 37°C for 48 hrs, one plate aerobically and 203 
one plate microaerophilically. The presence of C. jejuni was indicated by lack of 204 
growth aerobically and colonies with Campylobacter morphology that grew 205 
microaerophilically. In addition, Gram stains were performed on all presumptively 206 
Campylobacter positive samples. Oxidase strips (Oxoid MB0266) were used to 207 
further confirm that the samples were oxidase positive. 208 
In case of pre-inoculation testing, at day 16 cloacal swab (1 bird/pen) and overshoes 209 
(1 overshoe/pen) were tested for presence and absence of C. jejuni using the same 210 
procedure as reported for C. jejuni enumeration. 211 
Caecal volatile fatty acid analysis. The caecal digesta were gently flushed out 212 
in 30 ml universal sample containers and immediately stored at -80ºC until analysed. 213 
Samples were ground in the presence of solid CO2 to ensure homogeneity. They were 214 
then shaken with a known volume of water to extract the fatty acids. The extracts 215 
were spiked with 4-methylvaleric acid as an internal standard and then passed to the 216 
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Gas Chromatography (HP 5890 Series II GC; Agilent J & W 30m × 0.535mm × 1.00 217 
micon HP-FFAP column; FID detector) to determine the individual component 218 
composition by comparison with a series of standard solutions which were also spiked 219 
with an internal standard. Acetic, n-butyric, propanoic, n-valeric, iso-butyric and iso-220 
valeric acid were detected and results were expressed as mg/kg. 221 
Statistics 222 
For the in vitro tests, a single 5 µl aliquot extracted from a bead in a serially-diluted 223 
manner, grown on a CDDA plate was the statistical unit of measurement. A 224 
randomized complete block design with ten blocks and four treatments was used for 225 
in vivo studies. The individual bird sampled was the experimental unit for 226 
microbiological (C. jejuni and E. coli) and VFA analysis whereas the pen was the 227 
experimental unit for growth performance data. The microbiological data were log10 228 
transformed prior to analysis. Data obtained were subjected to Analysis of Variance 229 
(ANOVA) using a GenStat 16 statistical software package (IACR, Rothamstead, 230 
Hertfordshire, UK). Significance between treatments was determined using 231 
orthogonal polynomial contrasts. Where correlations are presented (identified using 232 
Genstat), all r
2
 are significant to at least P < 0.05 unless otherwise stated. All 233 
statements of significance are based on the probability level of P ≤ 0.05.  234 
RESULTS 235 
Nutrient composition and analysed TYPLEX
®
 Chelate of the experimental diets were 236 
within the expected range and are presented in Tables 1 and 2 respectively. 237 
Inhibitory impact of extracted TYPLEX
®
 Chelate from feeds on C. jejuni biofilm 238 
formation 239 
In vitro data showed that the addition of TYPLEX
®
 Chelate significantly reduced the 240 
ability of C. jejuni to adhere to plastic beads and form a biofilm (Table 3). For the 241 
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starter diet, the addition of TYPLEX
®
 Chelate extract at all concentrations reduced 242 
linearly the number of C. jejuni cells compared to the control group (0.5, 0.3 and 0.5 243 
log10 cfu/g reduction, respectively, P < 0.001). Similar results were observed for the 244 
grower diet; the addition of TYPLEX
®
 Chelate extract at 0.02 g/kg, 0.05 g/kg and 0.2 245 
g/kg reduced linearly the number of C. jejuni cells compared to the control group (0.4, 246 
1.4 and 1.0 log10 cfu/g reductions, respectively, P  <  0.001).  247 
Campylobacter infection and bird performance 248 
The seeded litter challenge model was successful in horizontal transfer of C. jejuni in 249 
birds within pens. Pre-inoculation cloacal swabs and samples cultured from overshoes 250 
were negative, whereas all caecal samples from all pens cultured positive for C. 251 
jejuni. The growth performance of birds during the starter (days 0-21), grower (days 252 
21 to 39) and overall growth period (days 0 to 39) is presented in Table 4. During the 253 
pre-challenge (starter phase), average weight gain (AWG) of all birds fed the 254 
TYPLEX
®
 Chelate supplemented diet were consistently higher compared to the 255 
T1control group (P < 0.05). However, the differences were only significant when 256 
birds fed T2 and T4 (0.02 and 0.20g/kg TYPLEX
®
 Chelate) were compared with T1 257 
(P < 0.05). This improvement in AWG also resulted into 3.6% lower (P < 0.05) 258 
mortality adjusted feed conversion ratio (FCR) values compared with T1. During the 259 
Campylobacter challenged period (grower phase) all birds fed TYPLEX
®
 Chelate 260 
(T2, T3 and T4) had 19.6% higher (P < 0.05) AWG compared to T1 (control group). 261 
This increase in AWG was also translated into 5.7% improvement in FCR of all birds 262 
fed TYPLEX
®
 Chelate (T2, T3 and T4) supplemented diets compared to control 263 
group (T1). The average feed intake (AFI) over the entire trial period was lower (P < 264 
0.05) for T3 (0.05g/kg TYPLEX
®
 Chelate) compared to T1 control. This shift in AFI 265 
resulted in significantly lower (P < 0.05) FCR for birds in T3 group compared to 266 
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control. The overall growth performance depicted similar trends and showed 2.9 and 267 
4.9% linear improvement (P < 0.05) in AWG in birds fed T2 and T3 (0.02 and 268 
0.20g/kg TYPLEX
®
 Chelate), respectively and 4.1 % lower (P < 0.05) FCR for birds 269 
fed all TYPLEX
®
 Chelate diets (T2, T3 and T4) compared to control (T1). The 270 
overall AWG and FCR values were positively correlated (r
2
 = 0.693, 0.822 271 
respectively; P < 0.05) whereas, AFI showed no correlation (r
2
 = 0.03; P > 0.05) with 272 
the inclusion level of TYPLEX
®
 Chelate in the diet. The birds remained healthy 273 
through out the experimental period, and the percentage mortality for treatment 1 to 4 274 
was 6.0, 6.5, 3.5 and 6.5% respectively. Mortality was not associated with treatment 275 
(P > 0.05).  276 
Effect of TYPLEX
®
 Chelate on caecal C. jejuni and E. coli colonization. 277 
Microbiological analyses of caecal samples showed a 0.8, 2.1 and 2.1 log10 cfu/g 278 
linear reduction (P < 0.05) in C. jejuni colonization in TYPLEX
®
 Chelate 279 
supplemented T2, T3 and T4 treatment groups respectively compared to T1 control 280 
(Table 5). Similarly, 0.6, 0.8 and 1.2 log10 cfu/g linear reduction (P < 0.05) in E. coli 281 
counts was recorded in birds that received 0.02, 0.05 and 0.20 g/kg TYPLEX
®
 282 
Chelate (T2, T3 and T4) compared with T1 control (Table 5). The Campylobacter spp. 283 
and E. coli counts were positively correlated with the inclusion level of TYPLEX
®
 284 
Chelate (r
2
 = 0.931, 0.952, respectively; P < 0.05). 285 
Effect of dietary TYPLEX
®
 Chelate on caecal VFA concentrations. 286 
Individual and total VFA concentrations in the caecal digesta are presented in Table 6. 287 
Total VFA concentrations increased by 31 and 26% (P < 0.05) in birds fed 0.02 and 288 
0.05 g TYPLEX
®
 Chelate /kg feed, respectively, compared to the control group. This 289 
increase was due to a general increase in most acids. Thus, feeding birds diets 290 
containing 0.02 and 0.05 g TYPLEX
®
 Chelate/kg feed increased (P < 0.05) the 291 
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concentration of acetic acid by 26 and 24 %, respectively, compared to the non-292 
supplemented T1 control. No additional increase in acetic acid concentration was 293 
observed when the inclusion rate of TYPLEX
®
 Chelate was further increased from 294 
0.05 to 0.20 g/kg feed. Propionic acid concentrations were also consistently higher in 295 
birds fed TYPLEX
®
 Chelate diets, but the differences were not significant (P > 0.05) 296 
when compared with the T1 control. Differences in the concentration of n-butyric acid 297 
were more profound and the concentration linearly increased (P < 0.05) by 75, 66 and 298 
41% in birds T2, T3 and T4 fed diets containing 0.02 and 0.05 and 0.20g TYPLEX
®
 299 
Chelate /kg feed, respectively, compared  with T1control . Also, n-valeric, iso-butyric 300 
and iso-valeric acids were produced in very small quantities, but followed the same 301 
trend, with significantly greater concentrations in birds fed T3 diets containing 0.05g 302 
TYPLEX
® 
Chelate/kg feed compared to T1 control.  303 
DISCUSSION 304 
The public health significance of C. jejuni infection and emergence of multi-antibiotic 305 
resistant species of Campylobacter demands development of new control strategies in 306 
addition to farm biosecurity measures to lower carriage of C. jejuni in live animals. 307 
To our knowledge, this is the first study to report that TYPLEX
®
 Chelate inhibits C. 308 
jejuni biofilm formation. The in vitro assay showed that TYPLEX
®
 Chelate (extracted 309 
from experimental diets) in a simulated gut environment reduced the ability of C. 310 
jejuni to adhere to plastic beads and form a biofilm. 311 
It is known that MOMP binds to multiple host cell membranes by promoting biofilm 312 
formation and auto-aggregation. It is the biofilm-forming ability of C. jejuni that 313 
enables the organism to survive in the environment and enter the food chain (Joshua 314 
et al., 2006). Based on our in vitro results it is likely that TYPLEX
®
 Chelate inhibits 315 
FlaA and MOMP-mediated adhesion of C. jejuni as evidenced by the reduction in 316 
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biofilm formation. The ability of C. jejuni to attach to surfaces and grow in biofilms, 317 
where they are protected from antibiotics, biocides, and other chemical or physical 318 
challenges, is a key factor in persistence of infection in humans (Costerton et al., 319 
1999; Stewart, 2002; Stoodley et al., 2004). As the TYPLEX
®
 Chelate inhibits 320 
biofilm formation it can therefore be helpful in farming and food processing to reduce 321 
cross-contamination of food products. This strategy offers an antibiotic-free method 322 
which will not encourage the emergence of resistance in pathogenic bacteria within 323 
the host organism. The inhibitory effect of TYPLEX
®
 Chelate on biofilm formation 324 
showed the same pattern in starter and grower diets.  325 
The birds in the current study were challenged at day 21 because Campylobacter spp. 326 
is rarely detected in commercial flocks of less than 3 weeks of age, regardless of 327 
production methods (Kazwala et al., 1990), species (Allen et al., 2011; Umar et al., 328 
2016) and biosecurity measures (Allain et al., 2014). The lag phase in colonization of 329 
poultry, even in the presence of positive birds suggests that a biological mechanism of 330 
colonisation resistance may be present in young birds due to maternal antibodies 331 
(Cawthraw and Newell, 2010). The relatively dry litter in the poultry house may also 332 
limit the ability of Campylobacter to survive in the small volume of excreta produced 333 
by birds in the first few weeks of life (Sparks, 2016). However, when the flock is 334 
infected, the majority of birds become colonized within 4 to 7 days after infection of 335 
the first bird (Sahin et al., 2015), and the overall prevalence rises as high as 100% at 336 
slaughter age (Barrios et al., 2006), without any apparent clinical manifestations in the 337 
chicken host (Kaino et al., 1988).  338 
The incidence of human campylobacteriosis is often associated with consumption of 339 
poultry products contaminated with C. jejuni and this, in turn, is linked to the number 340 
of C. jejuni present in the caeca of the bird (Wagenaar et al, 2006; Neal-McKinney et 341 
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al., 2014). As few as 500 cells of C. jejuni can cause infection (Black et al., 1988). 342 
There is no evidence for a “safe” level of Campylobacter contamination, as the 343 
minimum infectious dose will always be strain-specific. In general, it is considered 344 
that the risk of Campylobacteriosis increases as the number of Campylobacter on the 345 
bird increases (EFSA, 2009). Therefore, it is possible to reduce the incidence of 346 
human infection by lowering the number of C. jejuni in birds bound for the food 347 
supply. In this study, use of TYPLEX
®
 Chelate in broiler diets at 0.05 and 0.20 g/kg 348 
feed reduced the counts of caecal C. jejuni by up to 2 log10 cfu/g sample the counts of 349 
caecal C. jejuni in broilers aged 42 days. According to food safety risk analysis 350 
studies, this level of reduction in colonization may be able to reduce the public health 351 
risk associated with human campylobacteriosis (Rosenquist et al., 2003; EFSA, 2011). 352 
One of the mechanisms known to reduce Enterobacteriaceae (Gram-negative 353 
bacteria) in the intestinal microflora is the bacteriostatic effect of VFA’s in the caeca 354 
(Van Der et al., 2000). The current study showed that feeding broilers with diets 355 
supplemented with 0.02 and 0.05g TYPLEX
®
 chelate/kg feed resulted in increased (P 356 
< 0.05) caecal concentrations of total VFA, mainly due to higher production of acetic 357 
and n-butyric acid. High concentrations of VFA are indicative of fermentations by 358 
obligate anaerobic bacteria, reported to be an important source of energy for 359 
enterocytes and vital for intestinal health (Sunkara et al., 2012). It has been reported 360 
that increased concentrations of VFAs lower the intestinal pH, which is associated 361 
with suppression of pathogens (Kubena et al., 2001, Rehman et al., 2007). VFAs not 362 
only affect host functions but also serve as a carbon source for the endogenous 363 
bacteria and at high concentrations can exhibit toxic effects on bacteria. Chickens are 364 
omnivores, and the diversity of microbial communities in their intestinal tracts is 365 
related to their life-style. It has been proposed that the different nutritional 366 
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requirements for maintaining homeostasis of the microbiota communities in the gut 367 
would be due to different fermentable substrates available in the terminal ilea (Fang et 368 
al., 2012). Among the bacterial fermentation end-products in the chicken caecum, 369 
butyrate is of particular importance because of its nutritional properties for epithelial 370 
cells and pathogen inhibitory effects in the gut (Sun and O’Riordan, 2013). In the 371 
current study, the reduction in the proportion of acetic, butyric and valeric acids in the 372 
challenged unsupplemented control group (T1) could be due to C. jejuni. It has been 373 
reported that Campylobacter colonization reduces butyrate, iso-butyrate, valerate, and 374 
iso-valerate in the caecum (Awad et al., 2016).  375 
Furthermore, translocation of E. coli to the liver, spleen and caecum increases in birds 376 
infected with C. jejuni (Awad et al., 2016). Results from some of the epidemiological 377 
studies also reported an increase of E. coli in chicken carcasses that were infected 378 
with Campylobacter (Duffy et al., 2014). The results from this study suggest that 379 
Campylobacter infection may have an influence on the development of other 380 
microbial populations, such as E. coli, illustrated by the data on TYPLEX
®
 Chelate, 381 
used at higher doses. At 0.20 g/kg feed, TYPLEX
®
 Chelate not only caused a 2.1 382 
log10 cfu/g reduction in caecal C. jejuni colonization but also resulted in 1 2 log10 383 
cfu/g reduction in E. coli populations. In a previous study, we found that inclusion of 384 
TYPLEX
®
 Chelate in broiler diets without coccidiostats caused a significant 385 
reduction in coccidial oocyst counts and elevated the microbial dominance at 52-54% 386 
Guanine + Cytosine in comparison with non-supplemented diets, indicative of high-387 
performing healthy birds (Khattak et al., 1997). These results support the notion that 388 
TYPLEX
®
 Chelate may reduce the activities of pathogenic bacteria but favour 389 
beneficial bacteria and thus enhance growth performance. In addition, the assessment 390 
of minimum inhibitory concentrations (MIC) of TYPLEX
®
 Chelate to C. jejuni, E. 391 
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coli, and Salmonella enterica showed that TYPLEX
®
 Chelate did not inhibit the 392 
growth of these pathogens (personal communications with Dr Juha Apajalahti; 393 
Alimetrics Group Ltd). The MIC values were higher than 400mg/l for C. jejuni and 394 
higher than 200mg/l for E. coli and Salmonella, indicating that none of the enteric 395 
pathogens tested were inhibited by TYPLEX
®
 Chelate at concentrations relevant for 396 
animal feed applications. It is possible that the TYPLEX
®
 Chelate does not kill these 397 
pathogens but reduces their ability to adhere to the gut mucosa and thus lower their 398 
chances to compete with beneficial bacteria.  399 
The addition of TYPLEX
®
 Chelate to the diet consistently improved broiler AWG 400 
and FCR compared to non-supplemented control birds. It has been reported that C. 401 
jejuni can cause a significant decrease in weight gain of poultry (Awad et al., 2014a) 402 
and that there is a highly significant association between Campylobacter positivity 403 
and poorer FCR (Sparks, 2016). Campylobacter infection is found to significantly 404 
downregulate the gene expression of the sodium/glucose cotransporter (SGLT-1), 405 
peptide transporter (PepT-1), glucose transporter (GLUT-2), cationic amino acid 406 
transporter (CAT-2), excitatory amino acid transporter (EAAT-3) and the L-type 407 
amino acid transporter (y
+
LAT-2) in different parts of the gut (Awad et al., 2014b). 408 
Such decreased nutrient absorption not only explains the negative effect of 409 
Campylobacter colonization on body weight but this could be crucial for the 410 
persistence of Campylobacter itself. To colonize and invade, C. jejuni bacteria require 411 
adequate nutrients, mainly amino acids and Ca
2+
 (Fang et al., 2012; Awad et al., 412 
2015). Therefore, reduction in the intestinal uptake of nutrients by an avian host may 413 
increase carbon and nitrogen sources that are essential for bacterial growth (Guccione 414 
et al., 2008). The present study suggests that TYPLEX
®
 Chelate may also promote 415 
growth performance by enhancing intestinal nutrient absorption and reducing 416 
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colonization of C. jejuni. However, in addition to on-farm environmental conditions 417 
and host immune response (Lin, 2009), any negative effects on broiler body weights 418 
due to Campylobacter could also be strain-specific as different isolates of C. jejuni 419 
can have different colonization potential (Hermans et al., 2011).  420 
In conclusion, the data from the current studies suggest that TYPLEX
®
 Chelate 421 
reduces gut colonization of C. jejuni by inhibiting biofilm formation, increases the 422 
bacteriostatic effect of VFA and improve intestinal absorptive function. By reducing 423 
their adhesion power, it is likely that the spread of C. jejuni through other biological 424 
and non-biological routes would be reduced. In addition, disabling biofilm resistance 425 
may enhance the ability of existing antibiotics to fight infections that are refractory to 426 
current treatments and eventually help to reduce human cases of Campylobacteriosis.  427 
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Table 1. Composition of basal diets 637 
Ingredients 
(% unless otherwise stated) 
Starter diets 
(d 0-21) 
Grower diets 
(d 21-42 ) 
Barley  10.415 8.315 
Wheat 50 55 
Soya Ext Hipro 26 23 
Full fat Soya Cherwell 5 5 
L Lysine HCl 0.4 0.3 
DL-methionine 0.4 0.35 
L-threonine 0.15 0.15 
Soya Oil 4 4.5 
Limestone Trucal 52 1.25 1.25 
Monocalcium phosphate 1.5 1.25 
Salt 0.25 0.25 
Sodium bicarbonate 0.15 0.15 
Broiler Premix* 0.4 0.4 
Robenz 66G Premix (robenidine coccidiostat) 0.05 0.05 
Ronozyme WX (polysaccharidase enzymes 0.02 0.02 
Ronozyme P 5000 (CT) (phytase enzymes) 0.015 0.015 
Total 100% 100% 
Calculated analysis 
Fat (ether extract) 6.39 6.85 
Protein 21.84 20.64 
Fibre 3.08 3.02 
Ash 6.02 5.68 
ME-P 12.73 13.04 
Total lysine 1.43 1.28 
Available lysine 1.33 1.19 
Methionine 0.69 0.62 
Total methionine and cysteine 1.03 0.95 
Threonine 0.91 0.86 
Tryptophan 0.25 0.23 
Calcium 0.95 0.91 
Phosphorus 0.73 0.66 
Available phosphorus 0.48 0.42 
Sodium chloride 0.30 0.30 
28 
 
Sodium 0.17 0.17 
Analysed Nutrient composition 
Dry Matter 88.1 88.2 
Crude protein† 21.8 20.7 
Ether extract 6.66 7.12 
Iron (mg/kg) 135 99 
 *Premix provided per kg: vitamin  A,  2400 IU; vitamin D3,  1000 IU; vitamin E, 638 
10,000 IU; vitamin K3, 600 mg/kg; vitamin  B1, 400 mg/kg; vitamin  B2, 1,400 639 
mg/kg; pantothenic acid, 3,000 mg/kg; nicotinic acid, 10,000 mg/kg; vitamin B6, 640 
1,000 mg/kg; vitamin B12, 3,000 ug/kg; folic acid: 200 mg/kg; biotin: 40 mg/kg; 641 
copper, 2,000 mg/kg; zinc, 16,000 mg/kg; manganese,  20,000 mg/kg; iodine , 200 642 
mg/kg; selenium, 40 mg/kg; choline choride, 500 g: No added iron in premix. 643 
† Crude protein = Nitrogen x 6.25.  644 
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Table 2. Calculated and analysed value of TYPLEX
® 
Chelate in experimental diets. 645 
Treatment  Calculated Value  Analysed Value of 
TYPLEX
® 
Chelate in 
starter diets (g/kg)  
Analysed Value of 
TYPLEX
® 
Chelate in 
grower diets (g/kg) 
T1  0 0 0 
T2  0.02 0.02 0.02 
T3  0.05 0.06 0.04 
T4  0.20 0.19 0.26 
  646 
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Table 3. Inhibitory effect of TYPLEX
®
 Chelate on C. jejuni (NCTC11168) biofilm 647 
formation using plastic beads.  648 
 649 
Treatment Starter diet  
Log10 cfu/ml 
Grower diet 
Log10 cfu/ml 
T1  5.608 5.573 
T2  5.082 5.194 
T3  5.285 4.129 
T4  5.123 4.583 
SEM 0.040 0.076 
P-value’s for contrast 
T1 versus T2 <0.001 <0.001 
T1 versus T3 <0.001 <0.001 
T1 versus T4 <0.001 <0.001 
Linear <0.001  
N
o
. replicates/treatment = 18; cfu = colony forming units.   650 
SEM = standard error of the mean.  651 
T1= Control ((HCl/KCl) ; T2 = 0.02 g/kg TYPLEX
®
 Chelate ;T3 = 0.05 g/kg TYPLEX
®
 652 
Chelate; T4 = 0.20 g/kg TYPLEX
®
 Chelate. 653 
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Table 4. Effect of dietary treatments on growth performance of broilers
1
 654 
 655 
 Starter phase  Grower phase  Overall Performance 
 (d 0-21)  (d 21-39)  (d0-39) 
 AWG
2
 AFI
3
 FCR
4
  AWG AFI FCR  AWG AFI FCR 
Item (kg/bird) (kg/bird) (kg/kg)  (kg/bird) (kg/bird) (kg/kg)  (kg/bird) (kg/bird) (kg/kg) 
Treatment  
T1 0.773 1.077 1.400  0.381 2.948 1.611  2.618 4.025 1.544 
T2 0.821 1.076 1.314  0.428 2.915 1.579  2.695 3.991 1.495 
T3 0.776 1.024 1.327  0.461 2.865 1.533  2.660 3.890 1.471 
T4 0.829 1.085 1.316  0.479 2.943 1.543  2.748 4.028 1.472 
SEM 0.014 0.016 0.027  0.020 0.036 0.023  0.029 0.047 0.016 
P-values for contrast
5
 
T1 versus T2 0.002 0.979 0.004  0.027 0.361 0.182  0.02 0.484 0.007 
T1 versus T3 0.842 0.003 0.012  <0.001 0.031 0.002  0.181 0.009 <0.001 
T1 versus T4 <0.001 0.584 0.005  <0.001 0.889 0.007  <0.001 0.94 <0.001 
Linear 0.011 0.614 0.010  0.579 0.579 0.002  0.001 0.559 <0.001 
1
All means are average of 10 pens per treatment.  656 
2
 AWG = Average weight gain. 657 
3
 AFI = Average feed intake. 658 
4
 FCR = Feed conversion ratio.  659 
T1= Control; T2 = 0.02 g/kg TYPLEX
®
 Chelate; T3 = 0.05 g/kg TYPLEX
®
 Chelate; T4 = 0.20 g/kg TYPLEX® Chelate. 660 
5Significance level (P ≤ 0.05).  661 
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Table 5. Caecal microbial counts at 42 days of age 
1 
662 
Treatment Campylobacter spp.
1
 E. coli
1
 
 log10 cfu/g log10 cfu/g 
T1 5.86 7.83 
T2 5.03 7.24 
T3 3.81 7.05 
T4 3.74 6.64 
SEM 0.296 0.191 
P-values for contrast
2
 
1 vs 2 0.005 0.002 
1vs 3 <0.001 <0.001 
1vs 4 <0.001 <0.001 
Linear <0.001 <0.001 
1
All means are average of 20 (2 x culture plates/treatment). Campylobacter spp. cultured on 663 
CCDA medium, E. coli cultured on chromogenic agar; CFU = colony forming unit; SEM = 664 
standard error of the mean;  665 
T1= Control; T2 = 0.02 g/kg TYPLEX
®
 Chelate; T3 = 0.05 g/kg TYPLEX
®
 Chelate; T4 = 666 
0.20 g/kg TYPLEX
®
 Chelate 667 
2
Significant level (P≤0.05).   668 
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Table 6. Effect of experimental diets on the concentrations of volatile fatty acid 669 
(VFA; mg/kg) in the caecal content of broilers at 42 d of age. 670 
 671 
Item 
Acetic 
Acid 
n-Butyric 
Acid 
Propionic 
Acid 
n-Valeric 
acid 
Iso Valeric 
Acid 
Iso Butyric 
Acid 
Total 
VFA† 
Treatment 
T1 4785 1222 1048 179 214 126 7573 
T2 6009 2139 1232 228 212 135 9954 
T3 5979 2032 1199 255 310 175
b
 9567 
T4 5497 1728 1155 237 256 144
ab
 9018 
SEM 387.9 188.9 95.2 30.3 37 18.09 622.4 
P values for contrast
1
 
1 versus 2 0.003 <0.001 0.059 0.115 0.965 0.635 <0.001 
1 versus 3 0.003 <0.001 0.118 0.015 0.012 0.009 0.002 
1 versus 4 0.072 0.010 0.266 0.062 0.252 0.331 0.024 
Linear 0.091 0.022 0.342 0.040 0.058 0.108 0.050 
Means represents 2 birds per pen and 10 pens /treatment. 672 
1
Significance level (P ≤ 0.05).  673 
SEM = Standard error of differences of means.  674 
†Total VFA = sum of all individual volatile fatty acid (VFA). 675 
